CGON vs. RGEN, PCVX, EXEL, RVMD, HALO, KRYS, CRSP, IBRX, IMVT, and SWTX
Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and CG Oncology (NASDAQ:CGON) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
Repligen has a net margin of 2.44% compared to Repligen's net margin of 0.00%. CG Oncology's return on equity of 3.95% beat Repligen's return on equity.
Repligen received 392 more outperform votes than CG Oncology when rated by MarketBeat users. However, 81.82% of users gave CG Oncology an outperform vote while only 68.08% of users gave Repligen an outperform vote.
In the previous week, Repligen had 2 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Repligen and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.03 beat Repligen's score of 0.59 indicating that Repligen is being referred to more favorably in the media.
Repligen has higher revenue and earnings than CG Oncology.
97.6% of Repligen shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Repligen currently has a consensus price target of $197.75, indicating a potential upside of 32.64%. CG Oncology has a consensus price target of $63.75, indicating a potential upside of 95.67%. Given Repligen's stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Repligen.
Summary
Repligen beats CG Oncology on 11 of the 15 factors compared between the two stocks.
Get CG Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CG Oncology Competitors List
Related Companies and Tools
